vs
Side-by-side financial comparison of GENMAB A/S (GMAB) and TAKEDA PHARMACEUTICAL CO LTD (TAK). Click either name above to swap in a different company.
GENMAB A/S is the larger business by last-quarter revenue ($925.0M vs $4.3M, roughly 216.9× TAKEDA PHARMACEUTICAL CO LTD). GENMAB A/S runs the higher net margin — 36.3% vs 3.4%, a 32.9% gap on every dollar of revenue.
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, New Jersey, US, Genmab K.K. in Tokyo, Japan, Genmab Germany GmbH in München, Germany and Genmab (Suzhou) Co., Ltd. in Suzhou, China. Genmab is listed on the Co...
The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived th...
GMAB vs TAK — Head-to-Head
Income Statement — Q2 2025 vs Q1 2025
| Metric | | |
|---|---|---|
| Revenue | $925.0M | $4.3M |
| Net Profit | $336.0M | $144.2K |
| Gross Margin | 93.8% | 66.5% |
| Operating Margin | 38.9% | 5.0% |
| Net Margin | 36.3% | 3.4% |
| Revenue YoY | 18.7% | — |
| Net Profit YoY | 65.5% | — |
| EPS (diluted) | $5.42 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $925.0M | $4.3M | ||
| Q2 24 | $779.0M | — | ||
| Q1 24 | — | $4.0M | ||
| Q2 23 | $604.5M | — | ||
| Q2 22 | $458.5M | — |
| Q2 25 | $336.0M | $144.2K | ||
| Q2 24 | $203.0M | — | ||
| Q1 24 | — | $317.0K | ||
| Q2 23 | $193.6M | — | ||
| Q2 22 | $274.2M | — |
| Q2 25 | 93.8% | 66.5% | ||
| Q2 24 | 96.4% | — | ||
| Q1 24 | — | 69.1% | ||
| Q2 23 | 99.5% | — | ||
| Q2 22 | — | — |
| Q2 25 | 38.9% | 5.0% | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | — | 12.2% | ||
| Q2 23 | 35.2% | — | ||
| Q2 22 | 39.4% | — |
| Q2 25 | 36.3% | 3.4% | ||
| Q2 24 | 26.1% | — | ||
| Q1 24 | — | 7.9% | ||
| Q2 23 | 32.0% | — | ||
| Q2 22 | 59.8% | — |
| Q2 25 | $5.42 | — | ||
| Q2 24 | $3.13 | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $2.5B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $5.3B | $45.1B |
| Total Assets | $6.5B | $92.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $1.3B | $2.5B | ||
| Q2 24 | $622.0M | — | ||
| Q1 24 | — | $3.0B | ||
| Q2 23 | $1.6B | — | ||
| Q2 22 | $1.4B | — |
| Q2 25 | $5.3B | $45.1B | ||
| Q2 24 | $4.4B | — | ||
| Q1 24 | — | $47.3B | ||
| Q2 23 | $4.1B | — | ||
| Q2 22 | $3.5B | — |
| Q2 25 | $6.5B | $92.6B | ||
| Q2 24 | $5.6B | — | ||
| Q1 24 | — | $98.2B | ||
| Q2 23 | $4.6B | — | ||
| Q2 22 | $4.0B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $349.0M | — |
| Free Cash FlowOCF − Capex | $327.0M | — |
| FCF MarginFCF / Revenue | 35.4% | — |
| Capex IntensityCapex / Revenue | 2.4% | — |
| Cash ConversionOCF / Net Profit | 1.04× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | $349.0M | — | ||
| Q2 24 | $438.0M | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | $327.0M | — | ||
| Q2 24 | $430.0M | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | 35.4% | — | ||
| Q2 24 | 55.2% | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | 2.4% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
| Q2 25 | 1.04× | — | ||
| Q2 24 | 2.16× | — | ||
| Q1 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
TAK
Segment breakdown not available.
